Lunsekimig

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Lunsekimig
www.ebi.ac.uk

  • Immunoglobulin single chain of 5 VH (sc-5-VH), anti-[Homo sapiens IL13 (interleukin 13, IL-13)], anti-[Homo sapiens TSLP (thymic stromal lymphopoietin)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HAS)], monoclonal antibody sc-5-VH, humanized and chimeric, trispecific, pentavalent
  • immunoglobulin single chain of 5 vh sc 5 vh anti homo sapiens il13 interleukin 13 il 13 anti homo sapiens tslp thymic stromal lymphopoietin and anti homo sapiens alb albumin human serum albumin has monoclonal antibody sc 5 vh humanized and chimeric trispecific pentavalent
  • lunsekimig
  • Lunsekimig
  • lunsekimig [INN]
  • LUNSEKIMIG [USAN]
  • Lunsekimig [WHO-DD]
  • lunsekimig inn
  • lunsekimig usan
  • lunsekimig who dd
  • Single chain of 5 VH (sc-5-VH) humanized and chimeric (1-671)[VH anti-IL13 chimeric Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (87.6%) -(IGHD) -IGHJ2*01 (100%)/Homo sapiens IGHV3-23*04 (81.4%) -(IGHD) -IGHJ4*01 (85.7%), L50>R (45), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -35-mer hepta(tetraglycyl-seryl) linker (124-158) -VH anti-IL13 humanized (Homo sapiens IGHV3-43*02 (89.7%) -(IGHD) -IGHJ4*01 (92.9%) W118>R (274), CDR-IMGT [8.8.19] (184-191.209-216.255-273))(159-284) -9-mer glycyl-bis(triglycyl-seryl) linker (285-293) -VH anti-TSLP chimeric Vicpac /Homsap (Vicugna pacos IGHV3S53*01 (76.8%) -(IGHD) -IGHJ2*01 (100%)/Homo sapiens IGHV3-66*01 (72.9%) -(IGHD) -IGHJ1*01 (100%), L50>R (338), CDR-IMGT [8.7.11] (319-326.344-350.389-399)) (294-410)-9-mer glycyl-bis(triglycyl-seryl) linker (411-419) -VH anti-ALB humanized (Homo sapiens IGHV3-23*04 (88.5%) -(IGHD)-IGHJ1*01 (81.8%), L50>P (464), W118>S (524), CDR-IMGT[8.8.8] (445-452.470-477.516-523)) (420-534) -9-mer glycyl-bis(triglycyl-seryl) linker (535-543) -VH anti-TSLP chimeric Lamgla/Homsap (Lama glama IGHV3S1*01 (88.9%) -(IGHD)-IGHJ6*01 (85.7%)/Homo sapiens IGHV3-43*02 (82.8%) -(IGHD)-IGHJ5*02 (100%), L50>R (590), CDR-IMGT [10.8.18] (569-578.596-603.642-659)) (544-671)]
  • single chain of 5 vh sc 5 vh humanized and chimeric 1 671 vh anti il13 chimeric vicpac homsap vicugna pacos ighv3 3 01 87 6 ighd ighj2 01 100 homo sapiens ighv3 23 04 81 4 ighd ighj4 01 85 7 l50 r 45 cdr imgt 8 8 16 26 33 51 58 97 112 1 123 35 mer hepta tetraglycyl seryl linker 124 158 vh anti il13 humanized homo sapiens ighv3 43 02 89 7 ighd ighj4 01 92 9 w118 r 274 cdr imgt 8 8 19 184 191 209 216 255 273 159 284 9 mer glycyl bis triglycyl seryl linker 285 293 vh anti tslp chimeric vicpac homsap vicugna pacos ighv3s53 01 76 8 ighd ighj2 01 100 homo sapiens ighv3 66 01 72 9 ighd ighj1 01 100 l50 r 338 cdr imgt 8 7 11 319 326 344 350 389 399 294 410 9 mer glycyl bis triglycyl seryl linker 411 419 vh anti alb humanized homo sapiens ighv3 23 04 88 5 ighd ighj1 01 81 8 l50 p 464 w118 s 524 cdr imgt 8 8 8 445 452 470 477 516 523 420 534 9 mer glycyl bis triglycyl seryl linker 535 543 vh anti tslp chimeric lamgla homsap lama glama ighv3s1 01 88 9 ighd ighj6 01 85 7 homo sapiens ighv3 43 02 82 8 ighd ighj5 02 100 l50 r 590 cdr imgt 10 8 18 569 578 596 603 642 659 544 671

CAS registry numbers
  • 2770858-49-4
ChEMBL ID
CHEMBL5314848
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • VYR5R5XN5A

First in class
No
Orphan designation
No

Pharmacology name
lunsekimig
Type
Antibody
Drug name stem
-mig

  • Action
    Binding
    Action type
    Binding
    Target
    IL-13
    Gene symbol
    IL-13
    Median affinity
    11.29
    Affinity units
    pKd
  • Action
    Binding
    Action type
    Binding
    Target
    thymic stromal lymphopoietin
    Gene symbol
    thymic stromal lymphopoietin
    Median affinity
    11.77
    Affinity units
    pKd

Investigated indications

  • Condition
    Inflammation
    Highest recorded phase
    2
    Condition identifier
    MP:0001845
    Subject identifier
    D007249

  • Condition identifier
    EFO_0000274
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000341
    Highest recorded phase
    3
  • Condition identifier
    EFO_1002029
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0004979
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0004980
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005002
    Highest recorded phase
    3
  • Condition identifier
    MP_0001845

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    DVQLVESGGGVVQPGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREFVAALSGDGYSTYTANSVKGRFTISRDNSKNTVYLOMNSLRPEDTALYYCAAKLOYVSGWSYDYPYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAASGETFNNYAMKWVRQAPGKGLEWVSSITTGGGSTDYADSVKGRFTISRDNSKNTLYLOMNSLRPEDTALYYCANVPFGYYSEHFSGLSFDYRGOGTLVTVSSGGGGSGGGSEVOLVESGGGVVQPGGSLRLSCAASGSGFGVNILYWYRQAAGTERETIASITSGGITNYVDSVKGRFTISRDNSENTMYLOMNSLRAEDTGLYYCASRNIFDGTTEWGQGTLVTVSSGGGGSGGGSEVOLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVROAPGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLYLOMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGGVVOPGGSLRLSCAASGFTFADYDYDIGWFROAPGKEREGVSCISNRDGSTYYADSVKGRFTISRDNSKNTVYLOMNSLRPEDTALYYCAVEIHCDDYGVENFDFDPWGQGTLVTVSSA
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 180-254 $ 315-388 $ 441-515 $ 565-641 $ 595-647

Related records

Trials (9)

In development for (3)